Search Results - antonius+(tom)+oomens

4 Results

Sort By:

RSV-based Virus-like Particles as Vaccines

BACKGROUND Respiratory syncytial virus (RSV) is the single largest cause of viral pediatric bronchiolitis and pneumonia in the world; in 2015, 33.1 million RSV associated acute respiratory infections (ARI) in children resulted in 3.2 million hospitalizations and 59,600 deaths globally. This disease is also dangerous to people over 65 with 1.5...

Published: 5/17/2022 | Updated: 5/12/2022 | Inventor(s): Antonius (Tom) Oomens

Keywords(s):

Category(s): Technology Classifications > Biotech & Pharmaceutical

Incorporation of the Horseradish Peroxidase Gene in a Viral Genome Provides a Rapid and Cost-effective in vitro Method to Determine the Antiviral Potential of Antibodies or Drugs

BACKGROUND In-vitro virus neutralization assays are an important step in determining potential in-vivo efficacy of vaccines or (synthetic) anti-viral antibodies. Most recent micro-neutralization assays are based on luciferase or fluorescence read-outs. Viruses of interest are modified by inserting genes encoding luciferase or fluorescent proteins....

Published: 5/12/2022 | Updated: 4/7/2022 | Inventor(s): Pramila Lamichhane, Antonius (Tom) Oomens

Keywords(s):

Category(s): Technology Classifications > Research Tools, Technology Classifications > Biotech & Pharmaceutical

Engineered Respiratory Syncytial Viruses with Control of Cell-to-Cell Virus Transmission for Enhanced Safety of Live Virus Vaccines

ENGINEERED RESPIRATORY SYNCYTIAL VIRUSES FOR SAFE LIVE VIRUS VACCINES (OSU Ref # 2011-036) BACKGROUND Respiratory Syncytial Virus (RSV) is the largest viral cause of pediatric bronchiolitis worldwide, a respiratory disease that results in over 100,000 deaths per year. RSV can also cause adult lung diseases such as pneumonia and poses a serious risk...

Published: 4/19/2022 | Updated: 2/8/2022 | Inventor(s): Antonius (Tom) Oomens

Keywords(s): Biotech & Pharmaceutical

Category(s): Technology Classifications > Biotech & Pharmaceutical

A safe, self-limited, live RSV vaccine expressing pre-fusion conformation - stabilized fusion protein, and inducing both humoral and cellular anti-RSV immunity

A SELF-LIMITED LIVE RSV VACCINE INDUCING ANTI-PRE-FUSION F ANTIBODIES BACKGROUND Respiratory Syncytial Virus (RSV) is the single largest viral cause of pediatric bronchiolitis and pneumonia, with a high worldwide mortality, and there is no safe and effective vaccine. Ever since the encounter with vaccineenhanced disease (VED) during a formalininactivated...

Published: 4/19/2022 | Updated: 2/8/2022 | Inventor(s): Antonius (Tom) Oomens

Keywords(s): Biotech & Pharmaceutical

Category(s): Technology Classifications > Biotech & Pharmaceutical